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ABSTRACT
Recently, pancreatic RNase A was shown to inhibit tumor and metastasis 
growth that accompanied by global alteration of miRNA profiles in the blood and 
tumor tissue (Mironova et al., 2013). Here, we performed a whole transcriptome 
analysis of murine Lewis lung carcinoma (LLC) after treatment of tumor-bearing 
mice with RNase A. We identified 966 differentially expressed transcripts in LLC 
tumors, of which 322 were upregulated and 644 were downregulated after RNase 
A treatment. Many of these genes are involved in signaling pathways that regulate 
energy metabolism, cell-growth promoting and transforming activity, modulation 
of the cancer microenvironment and extracellular matrix components, and cellular 
proliferation and differentiation. Following RNase A treatment, we detected an 
upregulation of carbohydrate metabolism, inositol phosphate cascade and oxidative 
phosphorylation, re-arrangement of cell adhesion, cell cycle control, apoptosis, and 
transcription. Whereas cancer-related signaling pathways (e.g., TGF-beta, JAK/STAT, 
and Wnt) were downregulated following RNase A treatment, as in the case of the 
PI3K/AKT pathway, which is involved in the progression of non-small lung cancer. 
RNase A therapy resulted in the downregulation of genes that inhibit the biogenesis 
of some miRNAs, particularly the let-7 miRNA family.
Taken together, our data suggest that the antitumor activity and decreased 
invasion potential of tumor cells caused by RNase A are associated with enhanced 
energy cascade functioning, rearrangement of cancer-related events regulating cell 
growth and dissemination, and attenuation of signaling pathways having tumor-
promoting activity. Thus, RNase A can be proposed as a potential component of 
anticancer therapy with multiple modes of action.
INTRODUCTION
Over the past three decades, remarkable progress 
has been made in clarifying the mechanisms of 
cancer pathogenesis, encouraging the development 
of novel therapeutic strategies. Tumor development 
is accompanied by a variety of disorders, such as fast 
unlimited proliferation, resistance to tumor suppressors, 
loss of the initial differentiation, cell death resistance, 
replicative immortality, reprogramming of energy 
metabolism, evasion from immune surveillance, induction 
of angiogenesis, infiltrated growth and dissemination [1]. 
Chemotherapy remains the standard cancer treatment 
but is limited to universal impact on the proliferative 
properties of the tumor, which results in a loss of efficiency 
in some cases. Work addressing the properties and 
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functioning of tumor cells has enabled the development of 
targeted anticancer drugs, focused on those mechanisms 
necessary for tumor growth and progression. Over the last 
decade, the introduction of targeted therapies into clinical 
practice has increased the survival rate of cancer patients. 
Nevertheless, the most important feature of malignant 
disease is the deployment of regulatory cascades directed 
to maintaining tumor cell survival, thus enabling the 
damaged cells to adapt to a selective pressure and elude 
narrowly focused therapeutic effects. The complexity of 
the process of malignant transformation is enhanced by 
the fact that tumor is capable of recruiting the neighboring 
normal cells that form a tumor microenvironment and 
enhance tumor progression [1]. As a result, the tumor 
is a heterogeneous tissue containing regions of various 
degrees of differentiation, vascularity, migratory potential 
and, thus, possessing complicated intra- and extra-
cellular regulation. Thus, to overcome the heterogeneity, 
dynamism of molecular profile, and flexibility of 
regulation necessary for the survival of tumor cells, 
requires the application of drugs of multifactor action. The 
impact on the regulatory system of the tumor, controlling 
simultaneously multiple signaling pathways, can allow 
preventing the development of adaptive resistance of the 
tumor and appears to be an effective approach to struggle 
with neoplasia.
A rapidly growing amount of data indicates 
that miRNAs have a significant regulatory role in the 
vital activity of tumor cells [2, 3]. Hundreds of distinct 
miRNAs interact with target genes and operate as an 
important part of a large regulatory network, promoting 
tumorigenesis [2, 3]. Thus, ribonucleases, enzymes that 
can damage RNA and inhibit RNA-dependent regulatory 
processes in the tumor, represent promising alternative 
to conventional DNA-damaging agents and targeted 
drugs. It has been shown that the application of RNases 
as antitumor therapeutics helps to counterbalance the 
pathological molecular changes that occur within tumor 
cells and, thus, to control their malignant behavior. The 
antitumor and antimetastatic activity, as well as general 
system effects, of natural RNases have been demonstrated 
(e.g., BS-RNase from bovine testis [4-7], onconase 
from oocytes of Rana pipiens [8-10], bovine pancreatic 
RNase A [11-13], and microbial RNases [14-17]). The 
antitumor effects of Onconase [18, 19] and RNase A [20] 
were shown to be associated with an alteration in miRNA 
profiles in tumor cells. In malignant pleural mesothelioma 
cell lines, onconase was shown to significantly upregulate 
hsa-miR-17 and downregulate hsa-mir-30c, resulting in 
NFk-β inhibition and an increase in the chemosensitivity 
of tumor cells [18]. Onconase also downregulates 
intracellular miRNAs by cleaving miRNA precursors in 
Msto-211h mesothelioma cells [19].
Recently, using two murine tumor models, our 
group has shown that the pancreatic RNase A is capable of 
retarding primary tumor growth and efficiently inhibiting 
the development of metastases [11-13]. Using a murine 
Lewis lung carcinoma (LLC) model, we examined tumor 
and blood miRNA profiles after RNase A treatment and 
found that the antitumor and antimetastatic activities of 
the enzyme were associated with an increase in tumor 
miRNAs and decrease in serum miRNAs [20]. Because 
of the regulatory role of miRNAs, here we performed a 
whole transcriptome analysis of LLC following RNase A 
treatment by SOLiDTM sequencing. By this approach, we 
were able to identify key genes and event cascades crucial 
for the tumoricidal and invasive properties of tumor cells 
and, thus, explain the observed antitumor activity of the 
enzyme.
RESULTS
Design of the experiment and sequencing
RNase A treatment was shown to alter the tumor 
and blood miRNA profiles of LLC-bearing mice [20], 
decreasing the invasive potential of tumor cells and 
metastasis spreading [11-13]. Because there is still no 
evidence that RNase A penetrates into tumor cells or 
evades cytosolic ribonuclease inhibitor RI, it should be 
assumed that the observed effect is a systemic response 
of the tumor to treatment. Here, by SOLiDTM sequencing, 
we performed whole transcriptome analysis of LLC after 
treatment with RNase A and attempted to identify changes 
in the expression of key tumor survival cells.
A scheme of the experiment is shown in Figure 1. 
Following on protocol from our previous work [13, 20], 
two groups of mice with intramuscularly (i.m.) implanted 
LLC were treated with either saline buffer or RNase A. 
On the 15th-day post LLC transplantation and after ten 
injections of RNase A, tumor samples were collected and 
pooled according to groups. Total RNA was isolated and 
depleted of rRNAs. LC (saline treated) and LR (RNase 
A treated) cDNA libraries were prepared and sequenced 
using a SOLiDTM ABA 5.5 platform. The total numbers of 
reads for the LC and LR libraries were 5.3 × 10
7 and 3.1 × 
107, respectively.
Gene annotation
Reads were mapped to the Mus musculus reference 
genome (version NCBI37) using Bioscope software v.1.3. 
(ABI, USA). The differential expression analysis revealed 
966 differentially expressed transcripts (qFDR < 0.05), of 
which 322 were upregulated and 644 were downregulated 
in the tumor tissue of the LR group, compared to the LC 
group (Figure 2).
By gene ontology (GO) analysis (Biological Process 
[BP], Molecular Function [MF] and Cellular Components 
[CC]), we found that, for BP, most of the significant 
changes in expression were observed in genes involved 
in metabolic and cellular processes (GO:0008152 and 
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GO:0009987), biological regulation (GO:0065007), 
and response to stimulus (GO:0050896) (Figure 3). 
For MF, catalytic activity (GO:0003824) and binding 
(GO:0005488) were the most regulated terms. For CC, the 
major changes were observed in GO:0044464 (cell part) 
and GO:0043226 (organelle) (Figure 3).
Analysis of sequencing data
We used the online KEGG Automatic Annotation 
Server to assign the obtained gene sequences to those 
metabolic pathways with significance for cancer 
progression and cancer-related pathways promoting cell 
growth and transformation. Data were also analyzed using 
the Gene Card database. By this approach, we were able 
to identify tumor inductors and suppressors and miRNA-
associated genes, as well as transcription activators, 
repressors, regulators, and transcription factors (Table 1 
and Supplementary Tables 1–4). In our analysis we took 
into account a number of up- and downregulated genes 
in LR in comparison with LC and their involvement in 
regulation of pathways being important for survival of 
tumor cell.
We found that, in tumor tissue, RNase A treatment 
alters the expression of genes involved in metabolic 
pathways (25.1%), cancer-related events (responsible for 
cell growth, modulation of the cancer microenvironment 
and extracellular matrix components [17.9%]), pathways 
Figure 1: Experimental design and data mining. (A) Mice with i.m. transplanted LLC were treated with saline or RNase A at a 
dose of 0.7 μg/kg for 10 days starting on the 4th day after tumor transplantation. At 1 h after the last injection, tumor tissue samples were 
collected. (B) Total RNA was isolated and pooled according to groups. mRNA fractions were enriched by ribosomal RNA depletion and 
used for the construction of cDNA libraries. Libraries were sequenced using the standard SOLiD™ V5.5 (Applied Biosystems) protocols. 
Reads were mapped to the Mus musculus reference genome (version NCBI37), and analysis of differential expression was performed. 
Differentially expressed transcripts were annotated to GO terms and analyzed using KEGG database to assign pathway mapping.
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Figure 2: Volcano plot of the gene expression data. Green dots represent the genes for which transcription level was significantly 
different between samples of treated and untreated mice.
Figure 3: Functional annotation of genes changed more than 1.4-fold in tumor tissue of LLC-bearing mice after 
treatment with RNase A based on gene ontology (GO) categorization. (A) Biological Process [BP]. (B) Molecular Function 
[MF]. (C) Cellular Components [CC]. The green bars show the number of genes enriched in the sample of treated mice; red bars show the 
number of genes with decreased transcription in a group of treated mice.
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Table 1: Pathways affected by RNase A in tumor cells
Pathway or event Up-regulateda Down-regulatedb p-Valuec
Metabolic pathways
Amino sugar and 
nucleotide sugar 
metabolism, amino 
acids and nucleotide 
metabolism
4: Uap1l1, Mtap, Cant1, 
Impdh2





9: Pgls, Gaa, Bpgm, Mcee, 
B4galt2, Xylb, Pdk4, Aldoc, 
Lalba
8: Eno3, Galnt3, Alg10b, Csgalnact2, 





1: Akr7a5 3: Hsd11b1, Cyp27b1, Cyp26b1 2.075E-4
Inositol phosphate 5: Impa1, Gpaa1, Ip6k2, Plcd1, 
Pigb
1: Pi4k2b
Metabolism of lipids 
and fatty acids
11: Ech1, Hadh, Eci2, Acadvl, 
Pld3, Cbr4, Acat2, Phospho1, 
Plcxd2, Acsbg1, St3gal5





6: Ndufv3, Cox8a, Foxred1, 
Ndufb11, Bcs1l, Cox18




2: Nmnat3, Art5 1: Bst1 5.239E-6
Glutathione 
metabolism
2: Chac1, Haghl 3: Gclm, Gss, Gpx7 2.322E-7
Cancer-related events
Angiogenesis 2: Adamts10, Robo4 4: Cxcl5, Filip1l, Smoc2, Angptl1 - d
Apoptosis 8: Pcbp4, Steap3, Ctsh, Faim, 
Pycard, Plekhf1, Nol3, Dapk1
12: Lcn2, Ctsc, Gzmb, Hipk3, Phlda1, 




8: Rap2a, Myl12b, Emp2, 
Ptpn14, Bcas3, Abi3, Ajap1, 
Jup
12: S100a4, Col1a1, Cav2, Rab1, Thbs1, 
Rasgrf1, Shc4, Lrg1, Cxcl5, Itga7, Smoc2, 
Ccnd2
1.024E-11
Cell cycle control, 
transformation
4: Usp10, Mad2l2, Cdc26, 
Rnf122




3: Angpt2, Il2rb, Hsp90aa1 12: Col1a1, Thbs1, Il4ra, Csf3, Jak2, Tnc, 




4: Rras, Grap, Angpt2, Rgs14 4: Rasgrf1, Kras, Shc4, Pld1 9.345E-10
MAPK signaling 
pathway
6: Rras, Trib3, Map3k6, 
Hspa1b, Lamtor1, Dok4
11: Ccl7, Dusp6, Il1b, Cd14, Rasgrf1, 




2: Fam89b, Fmod 6: Ccl7, Thbs1, Ccl5, Acvr1b, Rbx1, Fst 2.863E-8
Wnt signaling 
pathway
5: Serpinf1, Wnt8a, Vangl1, 
Bcl9, Shisa2





responsible for cell growth promoting and transforming 
activity (25.4%), transcription regulation (23.5%), tumor 
inductors and suppressors (6.2%), and miRNA-processing 
machinery (1.6%) (Table 1 and Supplementary Tables 
1–4).
Metabolic cascades and pathways
The most significant alterations in gene expression 
were observed for the following metabolic pathways: 
amino sugar and nucleotide sugar metabolism; amino acids 
and nucleotide metabolism (four upregulated and eight 
downregulated genes, Table 1); carbohydrate metabolism 
(nine upregulated and eight downregulated genes, Table 1); 
metabolism of lipids and fatty acids (eleven upregulated 
and seven downregulated genes, Table 1). Oxidative 
phosphorylation (OXPHOS, six upregulated and three 
downregulated genes, Table 1, Supplementary Figure 1) 
and inositol phosphate metabolism (five upregulated and 
one downregulated genes, Table 1) were among those 
metabolic cascades that also undergo changes after RNase 
A treatment. Among key components of inositol phosphate 
metabolism, we observed upregulation for inositol(myo)-
1(or 4)-monophosphatase 1 (Impa 1), an enzyme that 
dephosphorylates myo-inositol monophosphate to generate 
free myo-inositol, a precursor of phosphatidylinositol, 
and thus an important modulator of intracellular signal 
transduction (Supplementary Table 1).
We also detected changes in cytochrome 
P450-associated metabolism (one upregulated and 
three downregulated genes, Table 1), nicotinate and 
nicotinamide metabolism (two upregulated and one 
downregulated genes, Table 1), and glutathione 
metabolism (two upregulated and three downregulated 
genes, Table 1).
Cancer-related events
Among cancer-related events (related to cancer 
progression, dissemination, and vitality), we observed 
changes in the expression of the genes involved in 
angiogenesis (two upregulated and four downregulated 
genes, Table 1), apoptosis (eight upregulated and twelve 
downregulated genes, Table 1), and cell cycle control and 
transformation (four upregulated and five downregulated 
genes, Table 1). The most affected events were cell 
adhesion, migration, invasion, and apoptosis (eight 
upregulated and twelve downregulated genes, Table 1). 
Among the eight upregulated genes observed for cell 
adhesion, migration, and invasion, we detected three 
genes positively regulating cell adhesion and affecting 
tumor dissemination (Ptpn14, Myl12b, and Emp2) (Table 
1, Supplementary Table 1). Among the downregulated 
genes, we detected Smoc2, which promotes proliferation 
and migration.
Among the upregulated genes in apoptosis, we 
detected five genes encoded proteins that function as 
positive apoptosis inductors, both for caspase-dependent 
and mitochondrial pathways (Pcpb4, Faim, Pycard, 
Plekhf1, and Dapk1). Among the downregulated genes 
involved in apoptosis, we detected two genes encoding 
negative apoptosis regulators (Hipk3 and Bcl2l2).
Cancer-related signaling pathways
Of the cancer-related signaling pathways, we 
detected a negative regulation of some tumor-promoting 
pathways in tumor tissue after RNase A treatment, 
including the PI3K/AKT (three upregulated and twelve 
downregulated genes), TGF-β (two upregulated and six 
downregulated genes), JAK/STAT (two upregulated 
and eleven downregulated genes), and canonical WNT 
Pathway or event Up-regulateda Down-regulatedb p-Valuec
JAK-STAT pathway 2: Il12rb1, Il2rb 11: Ccl7, Il4ra, Shcbp1, Ccl5, Csf3, Jak2, 




3: Tnnc2, Camk2g, Tnnc1 2: P2rx7, Tnc
MicroRNA in cancer - 5: Ezh2, Lin28a, Zcchc6, Tnrc6a, Zcchc11 8.498E-7
Cancer-associated - 12: Orai1, Dpp3, Arhgef1, Steap1, 
Arhgef11, Skp2, Tpd52, Mllt11, Laptm4b, 
Rfng, Ehbp1, Rbm6
- d
Tumor suppressors 3: Cyb561d2, Trit1, Pdgfrl 4: Armcx1, Brca2, Tssc1, Scai - d
aData are presented in Supplementary Table 1.
bData are presented in Supplementary Table 2.
cp-Value was calculated using tool for transcriptome annotation based gene list functional enrichment analysis ToppFun 
(https://toppgene.cchmc.org).
dGenes belonging to biological process on the base of Gene Card data.
Genes changed more than 1.4 folds in tumor tissue of LLC-bearing mice after treatment with RNase A were assigned to 
metabolic and cancer-related pathways based on KEGG annotation and analysis by Gene Card.
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signaling (six upregulated and eleven downregulated 
genes) pathways (Supplementary Tables 1 and 2, 
Supplementary Figures 2, 4, and 5). The strong negative 
regulation of the TGF-β signaling pathway was associated 
with an upregulation of Fam89b, which is a TGF-β 
pathway suppressor (Table 1, Supplementary Figure 5 
and Supplementary Tables 1 and 2). Some changes were 
also detected for the MAPK pathway (six upregulated 
and eleven downregulated genes, Supplementary Figure 
3) and RAS and calcium signaling pathways (Table 1, 
Supplementary Tables 1 and 2).
Cancer-associated genes and tumor suppressors
We also detected changes in the expression of 
genes usually considered as cancer-associated and 
whose increased expression is typical for various tumor 
types. In LLC tumors after RNase A treatment, we 
detected a downregulation of twelve such genes (Table 1, 
Supplementary Tables 1 and 2). Tumor suppressors were 
also affected by RNase A treatment (the upregulation of 
three genes and downregulation of four genes).
Genes associated with miRNA biogenesis
We have previously reported that the antitumor 
and antimetastatic activities of RNase A are associated 
with changes in the miRNA profiles of blood serum and 
tumor tissue [20]. Here, we found that five genes were 
downregulated, including Lin28a, Zcchc6, and Zcchc11, 
which act as suppressors during the biogenesis of the let-7 
miRNA family and in the terminal processing of miRNA 
precursors (Table 1, Supplementary Table 2).
Genes involved in transcription regulation
Interestingly, transcription was greatly affected by 
RNase A. We found that RNase A treatment resulted in 
significant changes in the expression of genes encoding 
components of the transcription machinery in tumor tissue 
(Supplementary Tables 3 and 4). Transcriptional regulators 
(five upregulated and 24 downregulated genes) and 
transcription factors (16 upregulated and 13 downregulated 
genes) were mostly affected. Transcriptional activators and 
co-activators (three upregulated and three downregulated 
genes) and repressors and corepressors (five upregulated 
and four downregulated genes) were also affected 
(Supplementary Tables 3 and 4).
Validation of expression level of genes - key members 
of pathways affected by RNase A
To validate our sequencing data, we tested the 
expression of some genes in tumor tissue after the 
treatment with RNase A by quantitative real-time 
PCR (qRT-PCR). At this stage we chose both up- and 
downregulated genes belonging to different processes 
and pathways promoting tumor survival and progression. 
Genes characterized by the highest LogFold but had 
low abundance in LC (close to 1) were not consider for 
validation. As a result following genes were chosen: Mtap 
(metabolism of amino sugars, nucleotide sugars, amino 
acids and nucleotides), Angptl4 (angiogenesis), Fam89b 
(a negative regulator of TGF-β signaling), Serpinf1 (Wnt 
signaling pathway), and Dusp6 and Map2k4 (MAPK 
signaling pathway). Genes Mtap (LogFold 0.71), Angptl4 
(LogFold 0.62), and Serpinf1 (LogFold 0.94) were chosen 
due to best ratio value in LC (RPKM)/LogFold (LR/LC) in 
their pathways. Fam89b and genes belonging to MAPK 
pathways were chosen on the base of its significance for 
pathway functioning.
In this experiment, we used rRNA-depleted samples 
of total RNA isolated from tumor tissue of RNase A treated 
and control mice. We found that Dusp6 (1.3-fold) and 
Map2k4 (1.5-fold) were downregulated following RNase 
A treatment (Figure 4, Table 2), which is in line with our 
sequencing data (Table 2). Mtap (1.6-fold), Fam89b (1.7-
fold), Serpinf1 (1.3-fold), and Angptl4 (2.5-fold) (Figure 4) 
were upregulated following RNase A treatment, that also 
correlate with our sequencing data (Table 2).
DISCUSSION
Ribonucleases (RNases) are potentially cytotoxic 
by virtue of their ability to degrade RNA and, therefore, 
to inhibit protein biosynthesis at transcription and 
translation stages. The cytotoxic effects of RNase are 
associated with: (1) catalytic cleavage of available RNA, 
including tRNA, rRNA, mRNA, and non-coding RNA 
(microRNAs), that affects gene expression [18, 21-24]; 
(2) non-catalytic electrostatic interaction of the exogenous 
enzyme with cell components [25]; (3) modulation of the 
membrane calcium-dependent potassium channels and ras-
oncogene functions [16, 26, 27]; (4) induction of apoptosis 
[28, 29]; and (5) the regulation of interplaying pathways 
[25, 30, 31].
Recently, we have shown that the RNase A-mediated 
inhibition of tumor growth and metastasis spreading in a 
murine LLC model [11-13] is accompanied by changes in 
the tumor tissue and blood miRNA profiles [20]. Next, we 
performed whole transcriptome analysis of tumor tissue 
after RNase A treatment and detected 966 differentially 
expressed transcripts involved in metabolic and signal 
Table 2: Comparison of levels of gene expression 
validated by qRT-PCR and sequencing








transduction pathways important for regulation of cancer 
cell proliferation, survival, and maintenance of malignancy 
(Table 1, Supplementary Tables 1–4). We also detected 
some changes in the activity of transcription machinery 
consisted in change of the spectrum of transcriptional 
activators, repressors, regulators and transcription factors 
(Supplementary Tables 3 and 4).
Among strongly affected metabolic pathways, 
we detected amino sugar and nucleotide sugar 
metabolism, amino acids and nucleotide metabolism, 
carbohydrate metabolism, and metabolism of lipids and 
fatty acids. OXPHOS (Supplementary Figure 1) and 
inositol phosphate metabolism were also significantly 
upregulated.
During the last five years, considerable knowledge 
has been accumulated on the bioenergetics of cancer 
cells, leading to a better understanding of the regulation 
of energy metabolism during oncogenesis. In tumor cells, 
in order to adapt the mechanisms of energy production 
to microenvironmental changes, as well as to differences 
in tumor energy needs or biosynthetic activity, there 
is interplay between glycolysis and OXPHOS. This 
metabolic flexibility is used to survive under hypoxia. 
Some studies have reported a reduction in OXPHOS 
capacity in multiple cancer types, whereas others have 
reported the opposite [32]. Here, we observed an increase 
in OXPHOS processes following RNase A treatment 
(Table 1, Supplementary Figure 1 and Supplementary 
Tables 1 and 2). Many tumors types are characterized by an 
absence of respiration, despite the presence of high oxygen 
concentrations (known as the Warburg effect) [33]. This is 
because of impaired mitochondrial function [34], resulting 
in an inhibition of OXPHOS processes. Thus, increased 
OXPHOS activity could be considered as evidence of a 
reversal of the cancerous phenotype. NADPH biogenesis, 
which is an essential mechanism by which both normal 
and cancerous cells maintain redox balance [35], was 
shown to be slightly upregulated after RNase A exposure. 
Given all aforementioned, we can conclude that these data 
are evidence for the increased energy demands of tumor 
cells following RNase treatment. Obtained data are in line 
with data about other ribonucleases, with the example of a 
nuclear-directed pancreatic ribonuclease PE5, which was 
shown to downregulate of multiple genes in cancer cells 
involved in deregulated metabolic pathways [36].
RNase A treatment resulted in re-arrangement of 
functioning of some pathways including angiogenesis, 
apoptosis, cell cycle control, and cell-cell contacts that 
lead eventually to positive regulation of cell adhesion and 
inhibition of tumor dissemination. Positive event in cell 
adhesion is an increase in expression of Ptpn14 that plays 
a role in the regulation of cell-cell adhesion, cell-matrix 
adhesion, cell migration, cell growth, and also regulates 
TGF-β gene expression, thereby modulating epithelial-
mesenchymal transition [37, 38]. Ptpn14 also functions as 
a tumor suppressor [39]. An increase in Emp2 expression, 
which regulates the plasma membrane expression of the 
integrin heterodimers Itga6-Itgb1, Itga5-Itgb3, and Itga5-
Itgb1, thereby resulting in modulation of cell-matrix 
adhesion [40], and Myl12b, which participates in focal 
adhesion and at tight junctions [41], should be considered 
as positive events in cell adhesion. An important finding 
of our study is the decrease in expression of Smoc2 that 
stimulates endothelial cell proliferation, migration, as well 
as angiogenesis [42].
Some ribonucleases were found to participate in 
the control of cell proliferation and migration. Mutations 
in RNase L gene might promote enhanced cell migration 
Figure 4: RT-qPCR analysis of expression levels of mRNA of Dusp6, Fam89b, Map2k4, Mtap, Serpinf1, and Angptl4 
genes in tumor tissue of LLC-bearing mice after treatment with RNase A. The expression of mRNAs was normalized to Hprt1 
and Ywhaz. Data are presented as mean ± SE. The level of the corresponding gene in the control (mice with LLC treated with saline buffer) 
was set at 1.
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and metastasis while RNase L knockdown in PC3 cells 
increased tumor growth and metastasis in vivo [43, 44]. 
Human secreted ribonuclease RNASET2 operates through 
the control of both the cytoskeletal actin assembly [45-47] 
and cell motility/migration patterns [48].
Changes in the expression of genes involved 
in apoptosis allow concluding about the activation of 
intrinsic mitochondrial pathway in tumor tissue after 
exposure to RNase A. We detected an upregulation of the 
genes Pycard, Plekhf1, and Dapk1, which activate the 
mitochondrial apoptotic pathway. The increase in Faim 
expression, which encodes a protein that participates in 
protection against death receptor-triggered apoptosis 
[49], also indicates an enhancement of the intrinsic 
mitochondrial pathway. The decrease in the expression 
of Gzmb encoding protein which activates caspase-3, -7, 
-9, and 10 and promotes caspase-dependent apoptosis, 
is further evidence for the attenuation of this pathway 
functioning. The upregulation of Pcbp4 expression, which 
affects cell proliferation by inducing apoptosis and cell 
cycle arrest in the G(2)-M phase and is implicated in lung 
tumor suppression [50], as well as the downregulation of 
negative apoptosis regulators, are the key changes in the 
regulation of apoptosis caused by RNase A.
We detected a negative regulation by RNase A 
of multiple tumor-promoting pathways, including the 
PI3K/AKT, TGF-β, JAK/STAT and canonical WNT 
signaling pathways (Supplementary Figure 2, 4 and 5 
and Supplementary Tables 1 and 2). The MAPK and 
PI3K/AKT pathways govern fundamental physiological 
processes, such as cell proliferation, differentiation, 
metabolism, cytoskeleton reorganization, and cell 
death and survival. Constitutive activation of these 
signal transduction pathways is a hallmark of cancer 
and dysregulation, and these pathways have been 
implicated in the initiation, progression and metastatic 
spread of lung cancer [51]. The JAK/STAT pathway is 
a key player in the development of various tumor types 
(e.g., gastric cancer [52], pancreatic cancer [53], and 
hematological malignancies [54]). Among the genes 
involved in the JAK/STAT and PI3K/AKT pathways, 
we detected a downregulation of the genes encoding the 
Januse kinases Jak2 and Jak3, which participate in the 
activation of proteins of STAT family, thereby promoting 
tumorigenesis [55].
Based on our findings, we cannot determine whether 
the MAPK pathway is likely to be overall upregulated or 
downregulated by RNase A treatment (Supplementary 
Figure 3 and Supplementary Tables 1 and 2). We 
detected an upregulation of Rras, which displays tumor-
promoting activity, and a downregulation of Dusp6, which 
participates in the inactivation of MAP kinases (Table 1). 
Nevertheless some positive effect on expression of the 
genes of MAPK pathway took place. We also detected a 
downregulation of Trib3, which regulates the activation 
of MAP kinases [56] and blocks Akt kinases promoting 
cell proliferation and survival [57]. We also observed 
downregulation of Map2k4, which has been shown to be 
overexpressed in osteosarcomas and associated with a 
poor response to treatment, tumor progression, and worse 
overall survival [58] (Table 1). Thus, RNase A alters the 
MAPK pathway by some extent, but no conclusions can 
be done on its overall up- or downregulation.
TGF-β-induced signaling pathways have either 
tumor-suppression or tumor-promoting effects in a 
cancer type-specific and stage-dependent manner [59]. 
At a later stage of tumor progression, TGF-β exerts 
metastasis-promoting activity associated with epithelial-
to-mesenchymal transition, modulation of cancer 
microenvironment and extracellular matrix components, 
inflammation, and immune suppression [60]. Here, 
we detected a strong negative regulation of the TGF-β 
signaling pathway in tumor tissue after RNase A treatment, 
which was associated with the upregulation of Fam89b 
which is a TGF-β pathway suppressor (according to 
UniProt data, by sequence similarity).
Abnormal activation of Wnt signaling has been 
implicated in many cancer types, including gastrointestinal 
cancers, leukemia, melanoma, and breast cancer [61]. 
Here, we observed a downregulation of Lrrfip2 following 
RNase A treatment which is an activator of the canonical 
Wnt signaling pathway [62], and together with Shisa2 and 
Hmgxb4 promotes the attenuation of Wnt signaling (from 
UniProt, by similarity). Thus, we conclude that RNase A 
negatively regulates the canonical Wnt pathway in LLC.
LLC has an epithelial origin and is related to human 
non-small cell lung cancer (NSCLC) [63]. Therefore, we 
attempted to evaluate the interplay between cancer-related 
signaling pathways affected by RNase A and NSCLC 
development pathways. According to our sequencing 
data, the PI3K/AKT, MAPK, and calcium signaling 
pathways, which are directly involved in NSCLC 
progression, are downregulated by RNase A treatment 
(Figure 5). Downregulation of these particular pathways 
can give an impact in observed antitumor effect of RNase 
A manifested in retardation of primary tumor growth and 
inhibition of metastasizing treatment [11-13].
Another important result of our study is the 
downregulation of genes encoding suppressors of miRNA 
biogenesis (Lin28a, Zcchc6, and Zcchc11) (Table 1  
and Supplementary Table 2). Lin28a prevents terminal 
processing of the let-7 family of miRNA [64]. Zcchc6 
and Zcchc11 act as suppressors of miRNA biogenesis 
by mediating the terminal uridylation of some miRNA 
precursors, including pre-let-7 (by Zcchc6 and Zcchc11) 
and mir-107, mir-143, and mir-200c (by Zcchc11) [65]. 
These data might account for the observed upregulation 
of a wide spectrum of miRNAs (including miRNAs of 
the let-7 family) in tumor tissue after treatment with 
RNase A [20].
Our findings are in line with other studies of the 
effect of cytotoxic ribonucleases on gene expression 
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profile of tumor cells. It was shown that onconase 
significantly affect apoptosis, transcription, inflammation 
and the immune response in human mesothelioma cells 
[66]. Pathways affected by onconase include MAPK 
signaling, cytokine-cytokine-receptor interactions, and 
Jak-STAT signaling [66]. In ovarian cancer cells onconase 
strongly up-regulated genes involved in transcription 
regulation, cell cycle and apoptosis, immune and stress 
response [67] while nuclear-directed human pancreatic 
RNase PE5 down-regulated multiple genes coded for 
proteins engaged in cell adhesion/migration and enzymes 
involved in deregulated metabolic pathways [68].
A possible mechanism of the antitumor activity of 
RNase A is depicted in Figure 6. We propose that, as soon 
as RNase A reaches the bloodstream after i.m. injection, 
its main targets are extracellular RNAs, including a 
whole set of non-coding RNAs (and miRNAs). In line 
with this hypothesis we observed previously a significant 
drop in miRNA levels in the bloodstream after RNase A 
exposure but no evidences of direct miRNA cleavage by 
RNase A in the blood have been obtained. Since miRNA/
Ago2 complexes as well as miRNA in the microvesicles 
are known to participate in the distant (similar to 
endocrine) regulation we observed global changes in 
miRNA profiling and whole transcriptome of tumor 
tissue. Here, we report changes in the expression of 966 
transcripts following RNase A treatment. Despite reports 
of the neutralization of RNase A by cytosolic RNase 
Figure 5: Genes involved in the progression of non-small cell lung cancer.
Figure 6: Proposed mechanism of antitumor activity of RNase A. RNase A therapy resulted in the boost of 116 miRNAs in 
tumour tissue and drop of 137 miRNAs in the bloodstream of mice with intramuscularly transplanted LLC and in the changes in the 
expression of 966 transcripts in tumor cells.
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inhibitor (RI) [69], we cannot exclude a potential effect 
of RNase A on intracellular RNAs because we have no 
data on intracellular localization of RI and the ability of 
extracellular RNase A to penetrate into the cells. Similar 
to angiogenin, RNase A can function as a transcriptional 
activator, as discussed in an earlier publication [20].
Our data suggest that the antitumor activity and 
the decrease in invasion potential of tumor cells by 
RNase A can be accounted for enhanced energy cascade 
functioning, rearrangement of cancer-related events 
regulating cell growth and dissemination, and attenuation 
of signaling pathways having tumor-promoting activity. 
Thus, we conclude that the antitumor effect of RNase A is 
realized via multilevel regulation that induces a systemic 
antitumor response.
MATERIALS AND METHODS
Tumor transplantation and design of animal 
experiment
All animal procedures were carried out in strict 
accordance with the recommendations for proper use and 
care of laboratory animals (ECC Directive 2010/63/EU). 
The protocol and this study were specifically approved by 
the Committee on the Ethics of Animal Experiments of 
the Administration of the Siberian Branch of the Russian 
Academy of Sciences (permit number: 5-06-2015).
Lewis lung carcinoma (LLC) cells having epithelial 
origin [63] were generously provided by Dr N.A. Popova 
(Institute of Cytology and Genetics, SB RAS).
At the start of the experiments, animal weight (mean 
± SD) was 20.2 ± 1.5 g. To perform LLC studies, ten 
animals per group were used. The number of animals in 
each group was chosen in accordance with the requirement 
to provide statistically significant data.
Twelve- to 14-week-old female C57Bl/6J mice 
were used. LLC cells (106) in 0.1 ml of saline buffer were 
injected (i.m.) into the right thighs of mice and, on the 
4th day after tumor transplantation, mice were treated 
with saline buffer (n=10) or RNase A (Sigma, USA) at a 
dose of 0.7 μg/kg (n=10). RNase A was administered in 
a volume of 0.1 ml i.m. daily, except for weekends. The 
total number of injections was 10. On day 15 after tumor 
transplantation, tumor samples were collected 60 min after 
the last injection of RNase A.
Sample processing and RNA extraction
Tumor pieces from mice treated with saline 
buffer or RNase A were pooled according to groups and 
homogenized. Total RNA was extracted immediately 
using TRIzol Reagent (Invitrogen, USA). The long RNA 
(>200 nt) fraction was separated from the short RNA 
(<200 nt) fraction using the mirVana miRNA Isolation 
Kit (Ambion, USA), according to the manufacturer’s 
protocols. Ribosomal RNAs were removed from the long 
RNA fraction using the RiboMinus Eukaryote Kit (Life 
Technologies, USA). Two rRNA-depleted fractions of 
total RNA were obtained: the RNA fraction from tumor 
tissue of control mice treated with saline buffer (RNA
C(-r)
) 
and an RNA fraction isolated from tumor tissue of mice 
treated with RNase A (RNA
R(-r)
).
Preparation of DNA libraries and sequencing
DNA libraries were prepared from RNA using 
the SOLiD™ Whole Transcriptome Kit (Applied 
Biosystems, USA), in accordance with the manufacturer’s 
recommendations. In brief, rRNA-depleted fractions of 
total RNA (350 ng of each) were fragmented with RNase 
III and precipitated by ethanol in the presence of glycogen. 
The obtained RNA fragments (70 ng for each library) 
were hybridized with the adapter mix A and incubated for 
ligation for 16 h at 4°C, followed by reverse transcription 
(RT) and RNase H treatment. Large-scale PCRs were 
performed using 18 cycles, both for samples isolated from 
tumors of control and experimental groups. The cycling 
conditions were 95°C for 30 s, 62°C for 30 s, and 72°C 
for 30 s. The obtained adaptor-ligated PCR products were 
then cleaned using the QIAquik Qiagen Gel Extraction Kit 
(Qiagen, USA) and size-selected using 6% PAGE gel. The 
piece of the gel corresponding to 150–200 bp was cut-out, 
divided into four vertical pieces, and the two central pieces 
were used for the generation of cDNA by PCR (the same 
cycling conditions as above, 15 cycles). Desalting of the 
eluted PCR products was performed using the QIAquick 
Gel Extraction Kit (Qiagen, Germany). Then, the PCR 
products were quantified using the Quant-iT™ dsDNA 
HS Assay Kit (Invitrogen). Templated bead preparation, 
emulsion PCR, and deposition were performed and, 
as a result, two cDNA-libraries were constructed: LC 
(saline treated) and LR (RNase A treated). Libraries were 
sequenced using the standard SOLiD™ V5.5 (Applied 
Biosystems) protocols.
Libraries were run on a single slide, each on its 
quadrant, with 50 nucleotides read length on the SOLiD™ 
5.5 system resulting, accordingly, in 5.3 × 107 and 3.1 × 107 
total number of reads. Sequencing data have been 
submitted to the GEO Database (accession number GEO 
GSE63758).
qPCR
The expression of Dusp6, Fam89b, Map2k4, Mtap, 
Serpinf1, and Angptl4 were evaluated using qPCR. 
cDNA synthesis was performed in a total volume of 40 μl 




, RT buffer (50 mM 
Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2), 10 mM 
DTT, 0.5 mM dNTPs, 100 pmol of random hexa-primers, 
and 20 units of M-MLV reverse transcriptase (ICBFM SB 
RAS, Russia). cDNA synthesis was carried out at 37°C 
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for 60 min. PCR amplification was carried out in a total 
volume of 20 μl using 5 μl of cDNA (10-2 dilution), 0.6 
units of Maxima Hot Start Taq DNA Polymerase (Thermo 
Scientific, USA), 1×PCR buffer, 1.5 mM MgCl
2
, 0.2 mM 
dNTPs, 1×EvaGreen (Biotium, USA), and 0.25 μM sense 
and antisense primers. The following primers were used: 
Dusp6 sense 5′-CCTGGAAGGTGGCTTCAGTA-3′, 
Dusp6 antisense 5′-AGTCCGTTGCACTATTGGGG-3′; 
Fam89b sense 5′-CAAGGAGATGGTGGGGCTG-3′, 
Fam89b antisense 5′-CTCCTCGTCATCAGACAGGC-3′; 
Map2k4 sense 5′-CATGCAGGGTAAGCGCAAAG-3′; 
Map2k4 antisense 5′- ATCCCAGTGTTGTTCAGGGG-3′; 
Mtap sense 5′-ATACTCCATTCGGCAAGCCAT-3′, Mtap 
antisense 5′-CTCTCTCAAGGACCCGCAAG-3′; Serpinf1 
sense 5′- TTCAAGGGGCAGTGGGTAAC-3′, Serpinf1 
antisense 5′- CAGGGGCAGGAAGAAGATGA-3′; 
Hprt1 sense 5′-TTGCTGACCTGCTGGATTAC-3′, Hprt1 
antisense 5′- AGTTGAGAGATCATCTCCAC-3′; Ywhaz 
sense 5′-CCTCAACTTCTCTGTGTTCTA-3′, Ywhaz 
antisense 5′-TGCTTCATCTCCTTGGGTATC-3′. The 
reaction was performed with an initial preheating at 94°C 
for 4 min and 40 cycles of 94°C for 40 s, 60°C for 30 s, 
72°C for 30 s, followed by a melting point determination. 
The expression level of each gene is indicated by the 
number of cycles needed for the cDNA amplification to 
reach a threshold. The amount of DNA is calculated from 
the number of cycles by using standard curves, and the 
results are normalized to Hprt1 and Ywhaz. Relative gene 
expression was calculated using the standard BioRad IQ5 
software (BioRad, USA). qPCR data were statistically 
processed using one-way ANOVA with post hoc Tukey 
test; p <0.05 was considered to be statistically significant. 
The statistical package STATISTICA version 10.0 was 
used for analysis.
Gene mapping and annotation
Reads were mapped to the reference Mus musculus 
genome (version NCBI37) using Bioscope software 
v.1.3 with default mapping parameters. Transcript 
counts extraction and transformation to RPKMs (reads 
per kilobase per million reads), followed by analysis of 
differential expression, was performed with Cufflinks 
software v.2.0.1 (Center for Bioinformatics and 
Computational Biology, USA) [70]. Feature extraction, 
reads per kilobase per million reads in the library 
(RPKM), where RPKM = the number of reads of a specific 
mRNA/(size of mRNA[kb] × total number of reads in the 
library[mln]).
Genes were annotated to GO terms using the 
PANTHER Classification System (http://pantherdb.
org). The comparative pathway mapping was done with 
the Pathview package for R statistical language. Before 
pathway mapping, Log2fold RPKM values were scaled 
to range between -1 and 1. Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways were assigned to the 
assembled sequences using the online KEGG Automatic 
Annotation Server (http://www.genome.jp/kegg/kaas/). 
The Gene Card database (http://www.genecards.org) 
was used for functional gene analysis. The Mouse 
Genome Informatics was used for mouse gene symbols 
identification. Tool for transcriptome annotation based 
gene list functional enrichment analysis ToppFun (https://
toppgene.cchmc.org) was used for pathway p-value.
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